TransDigm Co-COO Joel Reiss Has Sold $119 Million — 444 Transactions at the Defense Monopoly
Joel Reiss, Co-Chief Operating Officer of TransDigm Group, has sold $119 million across 444 transactions with 26 recent Form 4 filings at the controversial defense supplier.
Co-Chief Operating Officer Joel Reiss at TransDigm Group (TDG) has sold $119 million in stock across 444 transactions, including 26 recent Form 4 filings. The sole-source defense and aerospace parts supplier — valued at $80 billion — has one of the most active insider sellers in the industrials sector.
444 Transactions, $119 Million
Reiss's selling at TransDigm has been a long-running, systematic program. At 444 transactions, he averages one sale every few business days — a pace that reflects a heavily automated trading plan designed for continuous equity extraction. His most recent $5 million in sales continues the pattern without interruption.
The TransDigm Business Model
TransDigm's business model is unique — and controversial. The company acquires aerospace and defense parts manufacturers, often gaining sole-source positions on proprietary components. Once it controls the only approved supplier for a specific part, it raises prices aggressively. The Pentagon's Inspector General has repeatedly criticized TransDigm's pricing practices, finding markups of up to 9,400% on certain parts.
Despite the controversy, the model has been enormously profitable for shareholders. TransDigm's stock has risen from under $100 to over $1,400 over the past decade, generating spectacular returns.
Insider Profile
| Metric | Value |
|---|---|
| Insider | Joel Reiss |
| Title | Co-Chief Operating Officer |
| Career Sales | $119.0 million |
| Total Transactions | 444 |
| Recent Form 4 Filings | 26 |
| Recent Sales | $5.0 million |
| Shares Remaining | Still holds |
Defense Spending Tailwinds
TransDigm benefits directly from increased defense budgets and commercial aviation recovery. The company's aftermarket parts business — where it holds monopoly positions — generates enormous margins. Revenue grew 18% in the most recent fiscal year, and the stock trades near all-time highs.
Yet Reiss, one of the two executives running day-to-day operations, has been steadily reducing his exposure. At $119 million in total sales and counting, the Co-COO has extracted significant value while the stock appreciated.
The Consistency Factor
What distinguishes Reiss's selling is its sheer consistency. The 26 recent filings and 444 career transactions suggest this is not a reaction to any specific catalyst — it's a permanent, structural selling program. For a company that trades at 30x forward earnings in a capital-intensive industry, the insider's continuous bet-reducing is worth monitoring.
Track all TransDigm insider activity on the TDG stock page.
Related Research
Explore all researchKEYBANK NATIONAL ASSOCIATION/OH reported 27.38B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Retirement Systems of Alabama reported 29.98B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC reported 49.10B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Wasatch Advisors' 2026Q1 13F showed a $15.06B reported book led by HealthEquity, Ensign, Medpace and a set of small and mid-cap growth names.
Pzena Investment Management's 2026Q1 13F looked nothing like a mega-cap AI basket, with Magna, Cognizant, Tyson, Baxter and Bristol Myers among the top holdings.